高盛公司将泰格医药A股评级上调至买进，目标价77.10元人民币。

Core Viewpoint - Goldman Sachs has upgraded the rating of Tiger Medical's A-shares to "Buy" with a target price of 77.10 RMB [1] Group 1 - The upgrade reflects a positive outlook on Tiger Medical's performance and potential growth in the market [1]